Search results
Results From The WOW.Com Content Network
AstraZeneca expects a sales hit in China, one of its most important international markets. ... Adjusted earnings per share were $2.08, 20% higher than the year-ago period. ... and two new stock ...
Three growth stocks that look particularly cheap right now are AstraZeneca (NASDAQ: AZN), Uber Technologies (NYSE: UBER), and Zoom Communications (NASDAQ: ZM). 3 Cheap Growth Stocks to Buy in 2025 ...
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [13]
Total revenue rose 17% on a constant-currency basis to $12.94 billion for the three months ended June, while core earnings came in at $1.98 per share, compared with analysts' average expectation ...
With the lower re-negotiated a lower price of $21.5 billion between Johnson & Johnson and Guidant, Boston Scientific announced an unsolicited offer of $24.6 billion for Guidant (an offer of $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share). 26 2006 Johnson & Johnson: Guidant: 24.2 37
For premium support please call: 800-290-4726 more ways to reach us
The stock fell as much as 5.6% to 119.98 pounds in morning trade, with shares, which have gained nearly 18% this year, set for their biggest one-day drop in seven months if losses hold.
AstraZeneca (AZN) reported strong earnings Friday, including $22 billion, or 4% revenue growth, in the first half of the year, and kept its 2023 forecast stable.